Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis

Background: Type 2 inflammation is the principal determinant of asthma in children, and it leads to the downstream activation of eosinophils (EOS), the production of immunoglobulin-E (IgE), and increased levels of fraction of exhaled nitric oxide (FeNO). Dupilumab received the approval for the treat...

Full description

Bibliographic Details
Published in:World Allergy Organization Journal
Main Authors: Giorgio Piacentini, MD, Alessandro Fiocchi, MD, Gianluigi Marseglia, MD, Michele Miraglia Del Giudice, MD, Renato Cutrera, MD, Rossella Bitonti, MSc, Francesca Fanelli, MSc, Annalisa Stassaldi, MSc, Giuliana Nicolosi, MD, Gianluca Furneri, MSc
Format: Article
Language:English
Published: Elsevier 2024-08-01
Subjects:
Type 2 asthma
Dupilumab
Biomarker
Italy
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124000644

Internet

http://www.sciencedirect.com/science/article/pii/S1939455124000644

Similar Items